Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma

References

• Ries LAG. SEER Program (National Cancer Institute USA). Cancer incidence and survival among children and adolescents: USA SEER program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program (1999).
   Google Scholar
• Meyers PA, Gorlick R. Osteosarcoma. Pediatr. Clin. North Am.44(4), 973–989 (1997).
   PubMed Web of Science ®Google Scholar
• Pizzo PA. Principles and Practice of Pediatric Oncology (5th Edition). Pizzo PA, Poplack DG (Eds). Lippincott Williams & Wilkins, PA, USA (2006).
   Google Scholar
• Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr. Treat. Options Oncol.7, 444–455 (2006).
   PubMedGoogle Scholar
• Harris MB, Gieser P, Goorin AM et al. Treatment of metastatic osteosarcoma at diagnosis: a pediatric oncology group study. J. Clin. Oncol.16, 3641–3648 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized Phase III trial of the European Osteosarcoma Intergroup. J. Natl Cancer Inst.99, 112–128 (2007).
   PubMed Web of Science ®Google Scholar
• MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev.9(2), 125–136 (1990).
   PubMed Web of Science ®Google Scholar
• Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as modles for human cancer. Cancer Invest.8(8), 781–792 (2000).
   Google Scholar
• MacEwen EG, Kurzman ID, Rosenthal RC et al. Therapy for osteosarcoma in dogs with intravenous injection liposome-encapsulated muramyl tripeptide. J. Natl Cancer Inst.81, 935–938 (1989).
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Therapy of cancer metastasis by systemic activation of macrophages. Adv. Pharmacol.30, 271–326 (1994).
   PubMedGoogle Scholar
• Sone S, Matsuura S, Ogawara M, Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J. Immunol.132, 2105–2110 (1984).
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Brown NO, Hart IR. Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously. J. Biol. Response Mod.4, 298–309 (1985).
   PubMedGoogle Scholar
• McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J.26, 154–158 (2006).
   PubMedGoogle Scholar
• Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann. Surg. Oncol.14(10), 2887–2895 (2007).
   PubMed Web of Science ®Google Scholar
• Strober W, Murray PJ, Kitani A, Watanabe T. Signaling pathways and molecular interactions of NOD1 and NOD2. Nature Rev. Immunol.6(1), 9–20 (2006).
   PubMed Web of Science ®Google Scholar
• Lebourhis L, Benko S, Girardin SE. Nod1 and Nod2 in innate immunity and human inflammatory disorders. Biochem. Soc. Trans.35(6), 1479–1484 (2007).
   PubMedGoogle Scholar
• Girardin SE, Boneca G, Viola J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem.278(11), 8869–8872 (2003).
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through Nod2: implications for Crohn’s disease. J. Biol. Chem.278(18), 5509–5512 (2003).
   PubMed Web of Science ®Google Scholar
• Landmann R, Obrist R, Denz H et al. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. Biotherapy7, 1–12 (1994).
   Google Scholar
• Liebes L, Walsh CM, Chachoua A et al. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a Phase II study with patients with metastatic melanoma. J. Natl Cancer Inst.84, 694–699 (1992).
   PubMed Web of Science ®Google Scholar
• Frost H, Murray JL, Chaudri HA, Van Damme J. Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. J. Biol. Resp. Mod.9, 160–166 (1990).
   PubMedGoogle Scholar
• Kleinerman ES, Jia SF, Griffin J et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J. Clin. Oncol.10, 1310–1316 (1992).
   PubMed Web of Science ®Google Scholar
• Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J. Immunother.14, 286–292 (1993).
   PubMed Web of Science ®Google Scholar
• Nardin A, Lefebvre AL, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets6, 561–571 (2006).
   Google Scholar
• Bucana CD, Hoyer IC, Schroit AJ et al. Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am. J. Pathol.112, 101–111 (1983).
   PubMed Web of Science ®Google Scholar
• Galligioni E, Quaia M, Spada A et al. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells. Int. J. Cancer55, 380–385 (1993).
   PubMedGoogle Scholar
• Sone S, Utsugi T, Tandon P et al. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients. Cancer Immunol. Immunother.30, 357–362 (1990).
   PubMedGoogle Scholar
• Galligioni E, Santarosa M, Favaro D et al.In vitro synergic effect of interferon g combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells. Tumori80, 385–391 (1994).
   PubMedGoogle Scholar
• Kleinerman ES, Erickson KL, Schroit AJ et al. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res.43, 2010–2014 (1983).
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Murray JL, Snyder JS et al. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res.49, 4665–4670 (1989).
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Jessup JM, Fogler WE et al. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res.46, 994–998 (1986).
   PubMedGoogle Scholar
• Fogler WE, Wade R, Brundish DE, Fidler IJ. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice. J. Immunol.135(2), 1372–1377 (1985).
   PubMed Web of Science ®Google Scholar
• Dieter P, Hempel U, Kamionka S et al. Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides. Mediators Inflamm.8, 295–303 (1999).
   PubMed Web of Science ®Google Scholar
• Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother. Radiopharm.14, 121–128 (1999).
   PubMed Web of Science ®Google Scholar
• Asano T, Mcwatters A, An T et al. Liposomal muramyl tripeptide up-regulates interleukin-1 α, interleukin-1 β, tumor necrosis factor-α, interleukin-6 and interleukin-8 gene expression in human monocytes. J. Pharmacol. Exp. Ther.268, 1032–1039 (1994).
   PubMed Web of Science ®Google Scholar
• Dieter P, Ambs P, Fitzke E et al. Comparative studies of cytotoxicity and the release of TNF-α, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE. J. Immunol.155, 2595–2604 (1995).
   PubMed Web of Science ®Google Scholar
• Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun.3, 313–321 (1991).
   PubMed Web of Science ®Google Scholar
• Asano T, Mcintyre BW, Bednarczyk JL et al. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol. Res.7, 253–257 (1995).
   PubMed Web of Science ®Google Scholar
• Key ME, Talmadge JE, Fogler WE et al. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J. Natl Cancer Inst.69, 1198–1198 (1982).
   PubMedGoogle Scholar
• Talmadge E, Lenz BF, Collins MS et al. Tumor models to investigate the therapeutic efficiency of immunomodulators. Behring Inst. Mitt.74, 219–229 (1984).
   PubMedGoogle Scholar
• Talmadge JE, Lenz BF, Klabansky R et al. Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res.46, 1160–1163 (1986).
   PubMedGoogle Scholar
• Karpoff HM, Jarnagin W, Delman K, Fong Y. Regional muramyl tripeptide phosphatidylethanomamine administration enhances hepatic immune function and tumor surveillance. Surgery128, 213–218 (2000).
   PubMedGoogle Scholar
• Thomas K, Nijenhuis AM, Dontje BH et al. Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat. Clin. Exp. Metastasis13, 328–336 (1995).
   PubMed Web of Science ®Google Scholar
• Kurzman ID, MacEwen EG, Rosentahl RC et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin. Cancer Res.1, 1595–1601 (1995).
   PubMed Web of Science ®Google Scholar
• Vail DM, MacEwen EG, Kurzman ID et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin. Cancer Res.1, 1165–1170 (1995).
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Helfand S et al. Current studies of liposome muramyl tripeptide (CGP 19825A lipid) therapy for metastasis in spontaneous tumors: a progress review. J. Drug Target2, 391–396 (1994).
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Optimization and limitations of systemic treatment of murine metastases with liposomes containing muramyl tripeptide phosphatidylthanolamine. Cancer Immunol. Immunother.21(3), 169–173 (1986).
   PubMed Web of Science ®Google Scholar
• Fox LE, MacEsen EG, Kurzman ID et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma – a multicenter randomized double-blind study. Cancer Biother.10, 125–130 (1995).
   PubMedGoogle Scholar
• Teske E, Rutteman GR, vd Ingh TS, van Noort R, Misdorp W. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma. Anticancer Res.18(2A), 1015–1019 (1998).
   PubMed Web of Science ®Google Scholar
• Hisano G, Fidler IJ. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. Cancer Immunol. Immunother.14(2), 61–66 (1982).
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J. Clin. Oncol.9(2), 259–267 (1991).
   PubMed Web of Science ®Google Scholar
• Klimp AH, De Vries EG, Scherphof GL, Daemen T. Chemo-immunotherapy of ovarian cancer in a murine tumor model. Anticancer Res.20(4), 2585–2592 (2000).
   PubMedGoogle Scholar
• Bezault J, Walsh C, Tarcsay L et al. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 198356A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs. In Vivo7(6A), 487–491 (1993).
   PubMedGoogle Scholar
• Killion JJ, Kleinerman ES, Wilson R, Tanaka M, Fidler IJ. Sequential therapy with chemotherapeutic drugs and liposome-encapsultated muramyl tripeptide: determination of potential interactions between these agents. Oncol. Res.4(10), 413–418 (1992).
   PubMed Web of Science ®Google Scholar
• Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chilles without compromising immune stimulation? Cancer Immunol. Immunother.36(1), 45–51 (1993).
   PubMed Web of Science ®Google Scholar
• Fedorocko P, Hoferova Z, Hofer M, Prezani P. Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. Neoplasma50(3), 176–184 (2003).
   PubMed Web of Science ®Google Scholar
• Murray JL, Kleinerman ES, Cunningham JE et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J. Clin. Oncol.7, 1915–1925 (1989).
   PubMed Web of Science ®Google Scholar
• Creaven PJ, Cowens W, Brenner DE et al. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J. Biol. Resp. Mod.9, 492–498 (1990).
   PubMedGoogle Scholar
• Urba WJ, Hartmann LC, Longo DL et al. Phase I and immunomodulatory study of a muramyl tripeptide phosphatidylethanolamine. Cancer Res.50(10), 2979–2986 (1990).
   PubMedGoogle Scholar
• Kleinerman ES, Raymond AK, Bucana CD et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol. Immunother.34, 211–220 (1992).
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Gano JB, Johnston DA et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. (CCT) 18, 93–99 (1995).
   PubMed Web of Science ®Google Scholar
• Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother. Radiopharm.13, 363–368 (1998).
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Meyers PA, Raymond AK et al. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J. Immunother.17, 181–193 (1995).
   PubMed Web of Science ®Google Scholar
• Sculier JP, Gerain J, Body JJ et al. A pilot study on a muramyltripeptide lipophilic derivative entrapped into liposomes (CGP 19835A lipid) in patients with advanced non-small lung cancer. Drug Invest.6, 276–284 (1993).
   Google Scholar
• Verweij J, Judson I, Steward W et al. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. Eur. J. Cancer30A(6), 842–843 (1994).
   PubMedGoogle Scholar
• Meyers PA, Schwartz CL, Krailo MK et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol.23, 2004–2011 (2005).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MK et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival: a report from the Children’s Oncology Group. J. Clin. Oncol.26(9), 633–638 (2008).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD et al. In Reply. J. Clin. Oncol.26(18), 3104–3105 (2008).
   Web of Science ®Google Scholar
• Bielack SS, Marina N, Ferrari S et al. Osteosarcoma: the same old drugs or more? J. Clin. Oncol.26 (18), 3102–3103 (2008)
   PubMedGoogle Scholar
• Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J. Clin. Oncol.26(18), 3103–3104 (2008).
   PubMedGoogle Scholar
• Chou AJ, Kleinermen ES, Krailo MD et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. J. Clin. Oncol.26(4), 633–638 (2008).
   PubMedGoogle Scholar
• Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safety and effective agent against osteosarcoma pulmonary metastases. Expert Rev. Anticancer Ther.8(2), 151–159 (2008).
   PubMed Web of Science ®Google Scholar
• Dass DR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther.6, 3262–3270 (2007).
   Google Scholar
• Anderson P, Kopp L, Anderson N et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma). Expert Opin. Investig. Drugs17(11), 1703–1715 (2008)
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA et al. Initial testing (Stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer50(4), 799–805 (2008).
   PubMed Web of Science ®Google Scholar